NCT00511914View on ClinicalTrials.gov

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Seasonal Influenza Vaccine
Interventions
BIOLOGICAL

cTIV

One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle

Trial Locations (2)

35033

Betriebsaerztlicher Dienst, Standort Marburg, Baldingerstrasse

35041

Z29, Blutspendezentrale, Gebaude Z29, Behringwerke, Emil-von-Behring-Str. 76

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY